ScholarWorks@Korea University College of Medicine: Park, Jinny

Detailed Information

Park, Jinny (박진희)

Ansan Hospital (Department of Medical Oncology and Hematology, Ansan Hospital)

Research Area

Tel 031-492-5965
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Prognosis:10||Diffuse large Bcell lymphoma:8||prognosis:7||Chemotherapy:7||Rituximab:6||Acute myeloid leukemia:4||Chronic myeloid leukemia:4||Lung cancer:3||Elderly:3||Reactive oxygen species:3||Gastric cancer:3||chemotherapy:3||Lymphoma:3||NonHodgkin lymphoma:3||diffuse large Bcell lymphoma:3||Oxaliplatin:3||Survival:3||Cytotoxicity:3||stomach cancer:3||Hematopoietic stem cell transplantation:3||Clinical characteristics:2||decitabine:2||Nonsmall cell lung carcinoma:2||Practice guideline:2||itraconazole:2||Secondline:2||Oxidative stress:2||CD99:2||Mutation:2||Bone marrow:2||Pyrosequencing:2||protein kinase C:2||MDS:2||Docetaxel:2||Bortezomib:2||Pemetrexed:2||refractory:2||Korea:2||Marginal zone:2||Polycythemia vera:2||Thrombocythemia, essential:2||imatinib:2||Irinotecan:2||Autologous transplantation:2||Primary myelofibrosis:2||malignancy:2||Cisplatin:2||Gefitinib:2||Gemcitabine:2||Hematological malignancy:2||molecular response:2||S1:2||advance directive:2||Epirubicin:1||Erlotinib:1||Exon 20:1||Extranodal NK/Tcell lymphoma:1||FDGPET/CT:1||FLT3 Mutations:1||FOLFOX4:1||Ferritin:1||Firstline:1||Fragment analysis:1||Galactomannan Test:1||Genetics:1||Geriatric assessment:1||Germinal center B cells:1||Gold Nanoparticles:1||HER2:1||HL60:1||Hematological Malignancy:1||Hereditary spherocytosis:1||Hydroxy itraconazole:1||Hydroxyurea:1||Hypomethylating agent:1||IPSS:1||Immune thrombocytopenia:1||Immunochemotherapy:1||Immunohistochemistry:1||Immunostaining:1||Induction:1||Induction chemotherapy:1||Infection:1||Infusionrelated reaction:1||Internal Tandem Duplication:1||Intolerance:1||Itraconazole:1||KIT:1||KRAS mutation:1||Ki67:1||Korean:1||LRPSS:1||Lactate dehydrogenase:1||Leukemia, Myeloid, Acute:1||LowerRisk Prognostic Scoring System:1||Lung Neoplasms:1||Lung neoplasms:1||Lymphatic metastasis:1||Lymphomas:1||MAPK:1||MCF7:1||MCF7 cells:1||MMP9:1||MTT and TUNEL Assay:1||Marginal zone lymphoma:1||Mature Tcell neoplasm:1||Metabolic tumor volume:1||Molecular response:1||Monomorphic epitheliotropic intestinal Tcell lymphoma:1||Mucosaassociated lymphoid tissues:1||Multiple:1||Multiple myeloma:1||Mutations:1||Myelodysplastic syndrome:1||Myelofibrosis:1||Nras:1||NADPH oxidase:1||NFkappa B:1||Neural Progenitor Cell:1||Nilotinib:1||Nonsmall cell lung cancer:1||PPAR gamma:1||PTEN:1||PTEN (phosphatase and tension homologue):1||Palliative care:1||Pancreatic neoplasms:1||Philadelphia chromosome positive:1||Polycythemia Vera:1||Population study:1||Positronemission tomography:1||Postmarketing surveillance:1||Postsplenectomy:1||Predictive factor:1||Primary:1||Prognostic groups:1||Pseudolymphoma:1||RAR:1||Radiotherapy:1||Reactive thrombocytosis:1||Receptor, Epidermal Growth Factor:1||Receptor, epidermal growth factor:1||Relapse:1||Renal insufficiency:1||Resection:1||Response:1||Salvage treatment:1||Sanger sequencing:1||Sarcopenia:1||Screening PCR:1||Skin neoplasms:1||Small cell lung carcinoma:1||Smallcell lung cancer:1||Splenectomy:1||Stomach cancer:1||Stomach neoplasms:1||Survival analysis:1||TNFalpha:1||Thalidomide:1||Therapeutic drug monitoring:1||Thrombomodulin:1||Trastuzumab:1||Tumor burden:1||Tyrosine Kinase Domain Mutation:1||Tyrosine kinase inhibitor:1||Ultradeep sequencing:1||Waldeyer's ring:1||Weekly chemotherapy:1||acute myeloid leukaemia:1||acute myeloid leukemia:1||antiinflammatory:1||antioxidant:1||attitudes:1||autologous stem cell transplantation:1||azacitidine:1||biomarkers:1||bone marrow involvement:1||breast cancer:1||caregivers:1||chronic myeloid leukaemia:1||cisplatin:1||clonality:1||comparison:1||copanlisib:1||critical presentations:1||cytogenetic response:1||diallyl disulfide(DADS):1||dyad:1||empirical antifungal therapy:1||epsteinbarr virus:1||essential thrombocythemia:1||fisetin:1||gemcitabine:1||genome wide single nucleotide polymorphism array:1||hematologic stem cell transplant:1||hematology:1||high risk:1||human leukemia.:1||hyaluronic acid:1||hyaluronic acid synthase:1||hypocellular:1||imatinib cessation:1||immunochemotherapy:1||immunohistochemistry:1||invasion:1||irinotecan:1||knowledge:1||lenalidomide:1||leukemic cell differentiation:1||longterm data:1||marginal zone B cell lymphoma:1||marginal zone Bcell lymphoma:1||marginal zone lymphoma:1||matriptase:1||matrix metalloproteinase:1||matrix metalloproteinase9:1||medical imaging:1||mitomycin C:1||myelodysplastic syndromes:1||myeloproliferative neoplasms:1||nasal type:1||neoplasm invasiveness:1||newly diagnosed:1||nilotinib:1||nonHodgkin's lymphoma:1||nongastric:1||normal karyotype:1||nuclear diameter:1||observational study:1||outcome:1||p53:1||peripheral Tcell lymphoma:1||phase I/II trial:1||phase IV clinical trial:1||plantderived unsaturated fatty acid:1||prednisone:1||prognostic index:1||proteaseactivated receptor2:1||quality of life:1||qualityoflife:1||radotinib:1||reactive oxygen stress:1||relapse:1||relapsed or refractory:1||rituximab:1||s agammaglobulinemia tyrosine kinase:1||secondline therapy:1||smallcell lung cancer:1||surveillance:1||survival:1||topotecan:1||treatment:1||trough blood level:1||ultraviolet A:1||생존기간:1||임상 특징:1||5fluorouracil:1||폐암:1||AML:1||AMPactivated protein kinase:1||Adult:1||Anagrelide:1||Anaplastic carcinomas:1||Anemia:1||Antibiotic prophylaxis:1||Apoptosis:1||Atypical hemolytic uremic syndrome:1||Autoimmune disorder:1||B cell lymphoma:1||BCRABL1 tyrosine kinase:1||BIOMED2:1||Bacterial infection:1||Belotecan:1||Bloodstream infection:1||Bone marrow involvement:1||Brain metastases:1||Bruton&apos:1||Creactive protein:1||CALR:1||CD30:1||CML:1||CVP:1||Capecitabine:1||Carboplatin:1||Carcinoma, nonsmallcell lung:1||Central nervous system:1||Chop14:1||Chromosomal abnormalities:1||Compound K:1||Consolidation:1||Core binding factorpositive acute myeloid leukemia:1||Cytogenetics:1||DMSO:1||Dapsone therapy:1||Decitabine:1||Dexamethasone:1||Diffuse large B cell lymphoma:1||Diffuse large Bcell carcinomas:1||Diffuse large bcell lymphoma:1||Diffuse large cell lymphoma:1||Direct sequencing:1||Doxorubicin:1||Drug Resistance:1||Drug therapy:1||EGFR:1||EGFR TKI:1||Elderly AML:1||Empirical Antifungal Therapy:1||Empirical antifungal therapy:1||Epidermal growth factor receptor:1||

STATISTICS: Total View :12,822,981; Today View :5,930

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE